Skip to main content
TipRanks
Go Ultimate75% OFF

John Ratliff Insider Profile

4 Followers

John Ratliff, CEO, Covance Drug Development at Labcorp Holdings, holds 17.06K shares in Labcorp Holdings (Ticker: LH), holds 182.86K shares in IQVIA Holdings (Ticker: IQV).

John Ratliff's Trading History

LH
Labcorp Holdings
Apr 05, 2019CEO, Covance Drug DevelopmentUninformative Buy209.95K$6.32M
IQV
IQVIA Holdings
Nov 19, 2013President & COOInformative Sell4.89M$48.48M

You May Also Like

John Ratliff insider profile FAQ

What is the percentage of profitable transactions made by John Ratliff?
The percentage of profitable transactions made by John Ratliff is 0%.
What is the average return per transaction made by John Ratliff?
The average return per transaction made by John Ratliff is -34.60%.
What stocks does John Ratliff hold?
John Ratliff holds: LH, IQV stocks.
What was John Ratliff’s latest transaction?
John Ratliff’s latest transaction was an Uninformative Buy of $209.95K.
What was John Ratliff's most profitable transaction?
John Ratliff’s most profitable transaction was an Informative Sell of IQV stock on November 19, 2013. The return on the trade was -34.60%.
What is John Ratliff's role in Labcorp Holdings?
John Ratliff's role in Labcorp Holdings is CEO, Covance Drug Development.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.